
Five Things to Know About Esketamine
In March 2019, intranasal esketamine—a form of ketamine marketed as SPRAVATO™ CIII Nasal Spray*—was approved by the U.S. Food and

In March 2019, intranasal esketamine—a form of ketamine marketed as SPRAVATO™ CIII Nasal Spray*—was approved by the U.S. Food and

For many people coping with major depressive disorder—which includes different types of depression that persist for at least two weeks—antidepressants can